Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Decrypting the role of Cripto in tumorigenesis
Michael M. Shen
Michael M. Shen
Published August 15, 2003
Citation Information: J Clin Invest. 2003;112(4):500-502. https://doi.org/10.1172/JCI19546.
View: Text | PDF
Commentary

Decrypting the role of Cripto in tumorigenesis

  • Text
  • PDF
Abstract

The cell-surface associated molecule Cripto is overexpressed in a wide range of epithelial cancers, yet little is known about potential mechanisms by which Cripto expression might enhance tumorigenesis. A new study reveals that binding of Cripto to the TGF-β ligand Activin B can block Activin B–mediated suppression of cell proliferation. Furthermore, this study also demonstrates that antibody blockade of Cripto function may prove useful in the inhibition of tumorigenesis.

Authors

Michael M. Shen

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Schematic models for the role of Cripto in Activin and Nodal signaling. ...
Schematic models for the role of Cripto in Activin and Nodal signaling. For simplicity, TGF-β ligands and receptors are represented as monomers. (a) Activin signaling utilizes ActRIB and ActRII or ActRIIB, resulting in an active receptor complex and phosphorylation (P) of the type I receptor. (b) Nodal signaling requires Cripto, which is GPI-linked, in addition to ActRIB and ActRIIB. Nodal interacts with Cripto through the EGF motif, and requires the presence of an O-fucose modification (red F) on Cripto. (c–f) Four possible inactive complexes resulting in inhibition of Activin signaling by Cripto. Gray and colleagues (12) propose an inactive Cripto/Activin/ActRII complex (c) and do not detect direct interaction between Cripto and Activin (f). In contrast, Adkins and colleagues (1) propose three potential inactive complexes that do not include ActRII (d–f).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts